|
|
| Type |
Oral Presentation |
| Area |
Oral Presentation of Young Analytical Chemists Ⅱ |
| Room No. |
303호 |
| Time |
FRI 09:16-: |
| Code |
ANAL2.O-5 |
| Subject |
SERS-based immunoassay for the simultaneous detection of two prostate-specific antigens in clinical serum |
| Authors |
CHENGZIYI, 주재범1,*
한양대학교 바이오나노공학과, Korea
1한양대학교 생명나노공학과, Korea
|
| Abstract |
Numerous studies showed that the clinical accuracy of the prostate-specific antigen (PSA) determination can be improved by measuring the ratio of either free PSA (f-PSA) or complex PSA (c-PSA) relation to total PSA (t-PSA). Enzyme-linked immunosorbent assay (ELISA) and photoluminescence bioassays have been widely used for the quantitative analysis of PSA in clinical laboratory. However, those techniques have some technical drawbacks such as poor signal-to-noise ratio, limit of detection and simultaneous multiplex detection capability. Thus, scientists and medical doctors are still concerned about the ways to improve the PSA immunoassay test for the precise diagnosis of prostate cancer. In this work, a novel SERS-based immunoassay platform, using gold nanoparticles and magnetic beads, has been developed for the simultaneous detection of f-PSA and c-PSA. Here, XRITC- and MGITC-labelled gold nanoparticles have been used as SERS nanotags for the dual PSA marker assay. On the other hand, magnetic beads have been used as supporting substrates for the high density loading of immunocomplexes. Using this simultaneous assay platform, the SERS-based assay data for 30 clinical samples were obtained and compared with those measured by the chemiluminescence instrument installed in clinical laboratory. Compare with a parallel assay, the simultaneous assay shows more precise result and also has better reproducibility. This SERS-based technique provides a new insight for the fast and accurate diagnosis of prostate cancer. |
| E-mail |
imagicd86@gmail.com |
|
119th General Meeting of the KCS